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Abstract
Familial amyloidotic polyneuropathy (FAP) is a neurodegen-
erative disorder characterized by the extracellular deposition
of transthyretin (TTR), especially in the PNS. Given the
invasiveness of nerve biopsy, salivary glands (SG) from FAP
patients were used previously in microarray analysis; mito-
gen-activated protein (MAP) kinase phosphatase 1 (MKP-1)
was down-regulated in FAP. Results were validated by
RT-PCR and immunohistochemistry both in SG and in nerve
biopsies of different stages of disease progression. MKP-3
was also down-regulated in FAP SG biopsies. Given the
relationship between MKPs and MAPKs, the latter were
investigated. Only extracellular signal-regulated kinases 1/2
(ERK1/2) displayed increased activation in FAP SG and
nerves. ERK1/2 kinase (MEK1/2) activation was also
up-regulated in FAP nerves. In addition, an FAP transgenic
mouse model revealed increased ERK1/2 activation in per-
ipheral nerve affected with TTR deposition when compared
to control animals. Cultured rat Schwannoma cell line treat-
ment with TTR aggregates stimulated ERK1/2 activation,
which was partially mediated by the receptor for advanced
glycation end-products (RAGE). Moreover, caspase-3 acti-
vation triggered by TTR aggregates was abrogated by
U0126, a MEK1/2 inhibitor, indicating that ERK1/2 activation
is essential for TTR aggregates-induced cytotoxicity. Taken
together, these data suggest that abnormally sustained
activation of ERK in FAP may represent an early signaling
cascade leading to neurodegeneration.
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Familial amyloidotic polyneuropathy (FAP) is an autosomal
dominant neurodegenerative disorder characterized by the
extracellular deposition of transthyretin (TTR) amyloid ﬁbrils
throughout the connective tissue of several organs, particularly
in the peripheral nervous system (PNS) (Coimbra andAndrade
1971a,b). Morphologically, FAP is characterized by distal
axonal loss of ﬁbers that leads to the pathophysiological
condition associated with this disorder. In FAP, the most
common TTR variant presents a substitution of methionine for
valine at position 30 – TTR V30M. In the peripheral nerve,
TTR aggregates and amyloid ﬁbrils appear mainly in the
endoneurium in proximity of blood vessels and near Schwann
cells (SC) and collagen ﬁbrils (Coimbra and Andrade
1971a,b). In latter stages of disease progression, severely
affected nerves present endoneurium contents replaced by
amyloid, abundant collagen bundles, SC without axons and
ﬁbroblasts, and only a few nerve ﬁbers retain viability. In
ganglia, TTR amyloid deposits are present in the stroma in
close contact with satellite cells and a progressive loss of
neurons is observed (Hofer and Anderson 1975; Ikeda et al.
1987; Hanyu et al. 1989; Takahashi et al. 1991).
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Recently, it was shown that TTR aggregates bind to the
receptor for advanced glycation end-products (RAGE) and
that FAP tissues have increased expression of this receptor in
sites related to amyloid deposition (Sousa et al. 2000). The
TTR aggregates–RAGE interaction exerts cytotoxic effects
as it triggers activation of the nuclear transcription factor kB
(NFkB) (Sousa et al. 2000). FAP nerves show increased
expression of proinﬂammatory cytokines such as tumor
necrosis factor a (TNFa), interleukin-1b (IL-1b) and macro-
phage-colony stimulating factor (MCSF). Oxidative stress
also arises in FAP nerves by up-regulation of inducible nitric
oxide synthase (iNOS) (Sousa et al. 2001a), which produces
NO. Furthermore, caspase-3, a critical protease in the late
execution phase of apoptosis, was shown to be up-regulated
in axons of FAP nerves. Activation of these markers was
abrogated in cell culture by an anti-RAGE antibody or by the
soluble domain of RAGE.
These studies represented the ﬁrst step to understand the
involvement of RAGE in the pathophysiological changes in
FAP. The signaling mechanisms that mediate TTR aggre-
gates–RAGE interaction and NFkB activation are presently
unknown. The engagement of RAGE by a ligand triggers
activation of key cell signaling pathways, such as p21ras,
mitogen-activated protein kinases (MAPKs), NF-kB and
cdc42/rac, thereby reprogramming cellular properties (Yan
et al. 1994; Lander et al. 1997; Huttunen et al. 1999). For
example, the inhibition of RAGE–amphoterin interaction
suppressed activation of extracellular signal-regulated kinase
1/2 (ERK1/2), p38 and stress-activated protein kinases or jun
amino-terminal kinases (SAPKs/JNKs) MAPKs in rat C6
glioma cells (Taguchi et al. 2000).
ERK1/2 are serine-threonine kinases and are activated by
dual phosphorylation of threonine and tyrosine residues at the
activation domain carried out by MAPK kinase 1/2 (MEK1/2)
(Pearson et al. 2001). Active-ERK1/2 targets include several
transcription factors, signaling mediators, cytoskeletal pro-
teins and protein kinases. Because ERK1/2 substrates are
found in various subcellular compartments (Grewal et al.
1999), the biological outcome of ERK1/2 activation will
depend in part of the localization of ERK1/2 and its
accessibility to potential substrates within that compartment.
ERK1/2 cytoplasmic substrates are of particular importance in
neurons, in which ERK1/2 activation may occur at a consid-
erable distance from the nucleus. ERK1/2 activity is decreased
by either phosphotyrosine phosphatases or dual speciﬁcity
(serine-threonine and tyrosine) phosphatases also known as
MAPK phosphatases (MKPs) (Pearson et al. 2001).
Differential gene expression microarray data from human
FAP salivary glands (SG) has shown differences in genes
expressed in control and FAP SG, which included extracel-
lular matrix (ECM) remodelling genes; microarray results
were validated in nerve biopsies (Sousa et al. 2005). In the
microarray data, MAPK phosphatase 1 (MKP-1/CL100)
expression was 6-fold down-regulated in FAP. MKP-1 is an
inducible nuclear dual speciﬁcity phosphatase that can
dephosphorylate and inactivate ERK1/2, SAPK/JNK and
p38 MAPKs (Camps et al. 2000).
In the present study we questioned whether MKPs and
MAPKs are associated with FAP pathology.
Materials and methods
Subjects
Labial minor salivary glands (SG) biopsies were obtained from
V30M FAP patients prior to performing liver transplantation, the
only available treatment for this disorder. Control SG were from
age- and gender-matched non-FAP volunteer individuals that had no
evidence of infection. The collection of biopsies material was
approved by ethical committee of Hospital Geral de Santo Anto´nio,
Porto, Portugal, and participant subjects were volunteers. SG
collection and characterization was described previously (Sousa
et al. 2005). For immunohistochemical analysis, SG were collected
to 4% paraformaldehyde in phosphate-buffered saline (PBS). The
general characterization of SG consisted of TTR immunohisto-
chemistry and analysis of presence of amyloid deposits by Congo
red staining. SG with TTR deposition but without amyloid deposits
were classiﬁed as FAP 0, and SG with TTR deposition along with
amyloid deposits were classiﬁed as FAP. Sural nerve biopsy
specimens from FAP patients, asymptomatic carriers (FAP 0) and
controls (near relatives of FAP patients who ultimately turned out
not to have mutations in TTR) were available at the Hospital Geral
de Santo Anto´nio, Porto, Portugal, since this material was obtained
as part of the clinical diagnosis and evaluation of FAP, prior to the
current use of molecular diagnostic methods.
Microarray and semi-quantitative RT-PCR analysis
Salivary glands from four FAP patients and four control individuals,
age and gender matched, were collected and hybridization to the
U95A oligonucleotide array (Affymetrix, Memphis, TN, USA)which
represents12 000 human sequences was performed as described in
Sousa et al. (2005). Genes scored as increased or decreased in all
pairwise comparisons were selected. A gene was considered to have
modiﬁed expression if it averaged ‡ ± 2.5 fold change. In this analysis
we found down-regulation (6.2-fold ± 1.4) of mitogen-activated
protein (MAP) kinase phosphatase 1 (MKP-1/CL100). To validate the
microarray data at the RNA level, total RNA from salivary glands
from 3 control individuals and 3 FAP patients was isolated with Trizol
(Invitrogen, Carlsbad, CA, USA) and subjected to RT-PCR with the
Superscript II kit (Invitrogen). PCR was performed for 30 cycles at
95C for 30 s, 56C for 45 s and 72C for 1 min. Speciﬁc primers
were designed using PRIMER3 (http://frodo.wi.mit.edu/cgi-bin/
primer3/primer3_www.cgi) and the sequence from the National
Centre for Biotechnology Information database. Sense and antisense
primers were: for human MKP-1, 5¢-CTTGATCAACGTCTC-
AGCCA-3¢ and 5¢-AGAGGTCGTAATGGGGCTCT-3¢ and for
human b-actin, 5¢- AGAAAATCTGGCACCACACC-3¢ and
5¢-CCATCTCTTGCTCGAAGTCC-3¢. PCR products were quanti-
ﬁed from 1% agarose gels by densitometry using the Scion Image
software (Scion Corporation). Density values of RT-PCR products
were normalized with b-actin PCR product. Results are presented as
normalized density ± SD.
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Immunohistochemistry
For immunohistochemical analysis, nerve and SG parafﬁn sections
were deparafﬁnated, hydrated in a modiﬁed alcohol series, antigens
were unmasked by microwaving in 10 mM sodium citrate buffer
pH 6.0, endogenous peroxidase activity was blocked with 3%
hydrogen peroxide in methanol for 15 min and incubated in
blocking buffer (4% fetal bovine serum (FBS) and 1% bovine
serum albumin (BSA) in PBS) for 30 min at 37C in a moist
chamber. Incubation with primary antibody, at the appropriate
dilution in blocking buffer, was performed overnight at 4C in a
humidiﬁed chamber. Primary antibodies were rabbit polyclonal anti-
phospho-MEK1/2 (Ser217/221) 1 : 50-nerves; 1 : 100-SG, rabbit
polyclonal anti-MEK1/2 (1 : 100-nerves), mouse monoclonal anti-
phospho-p44/42 MAP kinase (Thr202/Tyr204) 1 : 20-nerves;
1 : 100-SG, rabbit polyclonal anti-p44/42 MAP kinase (1 : 100-
nerves and SG), mouse monoclonal anti-phospho-p38 (Thr180/
Tyr182) 1 : 20-nerves; 1 : 50-SG, mouse monoclonal anti-phospho-
JNK/SAPK (Thr183/Tyr185) 1 : 20-nerves; 1 : 50-SG, all pur-
chased from Cell Signaling Tecn. (Frankfurt, Germany); rabbit
polyclonal anti-MKP-1 (V-15) 1 : 100-nerves; 1 : 500-SG, goat
polyclonal anti-MKP-3 (N-18) 1 : 20-nerves; 1 : 100-SG, mouse
monoclonal anti-phospho-JNK (G-7); 1 : 20-nerves were from Santa
Cruz Biotech (Santa Cruz, Heidelberg, Germany). Antigen visual-
ization was performed with either biotin-extravidin-alkaline phos-
phatase or biotin-extravidin-peroxidase kits (Sigma, St Louis, MO,
USA), using Fast Red (Sigma) or 3-amino-9-ethyl carbazole (Sigma),
respectively, as substrates. On parallel control sections, primary
antibody was replaced by blocking buffer alone. Subsequent
immunohistochemistry was performed with either afﬁnity-puriﬁed
alkaline phosphatase- or peroxidase- conjugated secondary antibody
(Sigma). Semiquantitative immunohistochemistry (SQ-IHC) analysis
was performed using Scion Image software (freely downloaded from
Scion Corporation website). This application enables the measure-
ment of the area occupied by pixels corresponding to the immunoh-
istochemical substrate’s color that is normalized relatively to the total
area. Each slide used in the SQ-IHC was analyzed in 5 different
representative areas. To assess kinase activation, data is shown as the
ratio between the stained areas occupied by phospho-speciﬁc and
total-speciﬁc antibodies, within the same nerve biopsy. Results
shown represent percentage occupied area (± SD).
Proteins
Wild type recombinant TTR was produced from E. coli BL21
expression system and puriﬁed as previously described (Almeida
et al. 1997). Puriﬁed soluble TTR was detoxiﬁed using Endotoxin
Removing Gel (Pierce, Rockford, IL, USA). For preparation of TTR
aggregates, TTR was dialyzed against water, pH 7.0, and then
incubated with 0.05 M sodium acetate, pH 3.6, for 48 h at 22C. The
preparation was then centrifuged at 15 000 g for 30 min, the pellet
washed and resuspended in PBS, pH 7.4. Protein concentration was
determined by the Lowry method (Lowry et al. 1951). TTR
aggregates are composed of short ﬁbrils and amorphous aggregates
as assessed by ultrastructural analysis (Sousa et al. 2001b).
Cell culture assays
RN22 cells (rat Schwannoma cell line) were from the European
Collection of Cell Cultures. RN22 were propagated in 10 cm dishes
in monolayer and maintained at 37C in a humidiﬁed atmosphere of
95% and 5% CO2. Cells were grown in Dulbecco’s minimal
essential media (DMEM) (Gibco, Rockville, MD, USA) supple-
mented with 10% FBS (Gibco), 2 mM glutamine (Sigma) and
100 U/mL penicillin/streptavidin (Gibco) (complete media). For
ERK1/2 activation assays, cells were grown in complete media in
six-well plates. When 50% conﬂuence was reached, cells were
washed with PBS and starved in DMEM containing 1% dialyzed
FBS for 16 h. Subsequently, cells were treated with 1 lM of
soluble or aggregated TTR for the indicated time periods. For
studies using goat polyclonal anti-RAGE antibody (N-16)
(a-RAGE) (Santa Cruz Biotech) and non-immune (NI) puriﬁed
IgGs from goat serum (Sigma), following starvation, cells were
preincubated for 3 h with 30 lg/mL of aRAGE or NI, and then
treated with 1 lM TTR aggregates plus 10 lg/mL of aRAGE or NI
in DMEM containing 0.5% dialyzed FBS for 30 min. For caspase-3
activation assays, cells were grown in 25 cm2 ﬂasks. Activation of
caspase-3 was measured using the ﬂuorometric caspase-3 assay kit
(Sigma), following the manufacturer’s instructions. Brieﬂy, 80%
conﬂuent cells were incubated in assay media (DMEM containing
1% dialyzed FBS) with 2 lM of soluble or aggregated TTR for 24 h.
Where indicated cells were pre-incubated for 1 h with 1 lM U0126
(Calbiochem), a MEK1/2 inhibitor, and subsequently cells were
incubated with 5 lM U0126 alone or 5 lM U0126 with 2 lM TTR
aggregates. Next, cells were trypsinized and the cell pellet was lysed
in 100 lL of kit lysis buffer; 40 lL of each cell lysate sample was
used in duplicates for determination of caspase-3 activation. The
remaining cell lysate was used to determine total cellular protein
concentration with the Bio-Rad protein assay, using BSA as
standard. Values shown are the mean of quadruplicates of two
independent experiments. Student’s t-test statistical analysis was
used to determine statistical signiﬁcance between cells exposed to
assay media and cells exposed to different regulators.
Immunoblots
Following treatment with TTR, cells were washed twice with ice-
cold PBS, and lysed with 100 lL of lysis buffer (Cell Signaling
Tecn.) containing a protease inhibitor cocktail (Calbiochem, San
Diego, CA, USA). Cell lysates were centrifuged at 11 000 g and
protein in the supernatant was quantiﬁed with the Bio-Rad protein
assay. Equal amounts of protein were loaded in 12% SDS–PAGE
and transferred to nitrocellulose Hybond-C Extra (Amersham
Biosciences, Little Chalfont, Buckinghamshire, UK) using a
semidry transfer system. Blots were incubated with blocking buffer
(5% non-fat dried milk, and 50 mM NaF, to inhibit phosphatases, in
Tris buffered saline (TBS) with 0.1% Tween-20 (T)) for 1 h at room
temperature (RT). Subsequently, incubation with primary antibodies,
at the appropriate dilution, was performed overnight at 4C in 5%
BSA/TBS-T with 50 mM NaF. The primary antibodies used were
rabbit polyclonal anti-phospho-p44/42 MAP kinase (Thr202/
Tyr204) 1 : 1000, rabbit polyclonal anti-p44/42 MAP kinase
(1 : 1000), purchased from Cell Signaling Tecn., and rabbit
polyclonal anti-ERK 1 (C-16) 1 : 1000 from Santa Cruz Biotech.
After incubation with secondary sheep anti-rabbit IgGs peroxidase
conjugate (1 : 5000) (The Binding Site) in 1% non-fat dried milk
TBS-T for 1 h RT, blots were developed using the SuperSignal West
Pico Chemiluminescent Substrate kit (Pierce) and exposed to
Hyperﬁlm ECL (Amersham Bioscieneces). Blots were ﬁrst incuba-
ted with phospho-speciﬁc antibodies, stripped with Re-Blot Plus
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Mild Solution (Chemicon) according to manufacturer’s instructions,
reblocked, and then incubated with the respective anti-total protein
antibody for total protein normalization. Quantitative analysis of
immunoblot images was performed using the Scion Image software
(Scion Corporation). Results are shown as the squared pixels ratio
between phospho-p44/42 MAPK and total-p44/42, and represented
as fold activation relatively to cells exposed to assay media.
Nerve preparation
Transgenic mice bearing the human TTR V30M in a TTR-null
background (Kohno et al. 1997), were compared to TTR-null
(Episkopou et al. 1993) and wild type mice. Mice were killed by
cervical distension. Nerves were rapidly excised and frozen in dry
ice. In order to analyze ERK1/2 activation, peripheral nerves were
ground into powder with a frozen pestle in dry ice and homogenized
in lysis buffer (5 mM EDTA, 2 mM EGTA, 20 mM MOPS pH 7.0,
30 mM sodium ﬂuoride, 20 mM sodium pyrophosphate, 1 mM
sodium orthovanadate, 40 mM b-glycerophosphate, 0.5% triton
X-100, pH 7.2) supplemented with protease inhibitor cocktail set III
(Calbiochem). Homogenate samples were centrifuged at 16 000 g
for 30 min, and supernatants assayed for protein concentration by
the Bio-Rad method.
Statistical analysis
Group values, expressed as the mean ± SD, were compared by
Student’s t-test, and p-values of less than 0.05 were considered
signiﬁcant.
Results
MKP-1 and MKP-3 expression is down-regulated in FAP
Gene expression microarray data from human FAP salivary
glands (SG) showed down-regulation (6.2-fold ± 1.4) of
mitogen-activated protein (MAP) kinase phosphatase 1
(MKP-1/CL100). We validated the microarray data both
by RT-PCR and semi-quantitative immunohistochemistry.
RT-PCR of MKP-1 mRNA in human SG indicated a down-
regulated expression in FAP when compared to controls, as
shown in Fig. 1a and chart, conﬁrming the microarray
results. By semi-quantitative immunohistochemistry, amy-
loid laden SG from FAP patients showed a signiﬁcant down-
regulation of MKP-1 (Fig. 1b upper panels and chart),
validating the microarray results. MKP-1 immunostaining
was more abundant in the cytoplasm of the stratiﬁed cuboidal
epithelial lining present in excretory ducts than in the
nucleus. We then performed immunohistochemical analysis
for MKP-1 in FAP nerve biopsies in different stages of
disease progression. At later stages of FAP progression, when
compared with controls and asymptomatic carriers (FAP 0),
MKP-1 expression was down-regulated in axons (as docu-
mented in Fig. 1b lower panels and chart). To test whether
the expression of other dual speciﬁcity MAP kinase phos-
phatases (MKPs) could be affected in FAP, we studied
MKP-3, which speciﬁcally inactivates ERK1/2 when com-
paredwith JNK and p38MAPKs.MKP-3was down-regulated
in FAP 0 SG as well as in SG from FAP patients (Fig. 1c upper
panels and chart). The immunostaining was exclusively
cytoplasmatic in the epithelial lining of excretory ducts.
However, in human nerve biopsies, MKP-3 was up-regulated
in axons of the FAP 0 asymptomatic stage as compared to
controls, but MKP-3 levels at the symptomatic stage did not
differ from controls (Fig. 1c lower panels and chart).
ERK1/2 activation is up-regulated in FAP
The diminished expression of MKPs in FAP suggests that
MAPKs cascades might be up-regulated in FAP. Semi-
quantiﬁcation of MAPKs by immunohistochemistry of FAP
SG did not show activation of p38 and JNK MAPKs when
compared to control SG (data not shown). However, ERK1/2
MAPK activation in FAP SG showed a marked up-regulation
beginning at FAP 0 and persisting in the FAP stage. Often
phosphorylated ERK1/2 (pERK1/2) translocation to the
nucleus of stratiﬁed cuboidal epithelial lining in excretory
ducts was observed, whereas in controls a cytoplasmic
localization was present (Fig. 2a and chart). MAPKs were
also assessed in human FAP nerve biopsies. Consistently
with the analyses of human SG, intensity of immunostaining
for phosphorylated forms of p38 and JNK was not statisti-
cally different in FAP and control nerves (data not shown).
However, increased ERK1/2 phosphorylation was evident in
human FAP nerves. In asymptomatic carriers (FAP 0),
activated ERK1/2 was approximately 3-fold increased in
axons, whereas pERK1/2 was almost absent in controls.
Total ERK1/2 (tERK1/2) levels were similar in the two types
of samples (Fig. 2b and chart). At a later symptomatic stage,
phosphorylation levels of ERK1/2 were lower, however,
tERK1/2 levels also decreased, leading to a sustained ERK1/
2 activation, when compared to normal specimens (Fig. 2b
and chart). ERK1/2 was observed in several cell types,
neuronal axons were the main cellular structure with positive
staining. These results correlate well with the decreased
expression of MKP-1 seen in nerves from FAP patients.
Up-regulation of ERK1/2 detected in asymptomatic carriers
is not explained by the actions of MKP-1 and -3 and
additional mechanisms might intervene at this stage, such as
MEK1/2 activation. In an attempt to analyze ERK1/2
activation in vivo, we used a transgenic mouse model that
expresses human TTR V30M in a TTR-null background.
These mice when older than 9 months of age develop TTR
amyloid deposits in several organs within the gastrointestinal
tract, and at the age of 24 months the pattern of amyloid
deposition is similar to the one seen in FAP autopsies except
for the absence of TTR deposition in the peripheral nerve
(Takaoka et al. 1997). When we analyzed protein extracts
from TTR V30M mice peripheral nerve, we found a 2-fold
increased activation of ERK1/2 in older animals (17 months
of age) when compared with younger ones (2 months of age;
Fig. 2c). The observed activation was not age-dependent,
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(a)
(b)
(c)
Fig. 1 MKP-1 and MKP-3 expression in FAP. (a) RT-PCR analysis of
RNA extracted from salivary glands of control (C) individuals and FAP
patients. MKP-1 (upper lane) and b-actin (lower lane). Chart, Densi-
tometry of MKP-1/b-actin RT-PCR amplifications in control (n ¼ 3) and
FAP (n ¼ 3) SG biopsies. **p < 0.008, compared to control group. (b)
MKP-1 immunohistochemistry of representative SG (upper panels) and
nerves (lower panels) from control individuals (left panels), FAP 0
(middle panels) and FAP patients (right panels). Bar, 20 lm. Chart
(MKP-1), Quantitation of immunohistochemical images of MKP-1
staining in SG excretory ducts and nerves. (c) MKP-3 immunohisto-
chemistry of representative SG (upper panels) and nerves (lower
panels) from control individuals (left panels), FAP 0 (middle panels) and
FAP patients (right panels). Bar, 20 lm. Chart (MKP-3), Quantitation of
immunohistochemical images of MKP-3 staining in SG excretory ducts
and nerve. Data are represented as percentage of occupied area ± SD
for SG controls (n ¼ 6), FAP 0 (n ¼ 4) and FAP patients (n ¼ 6), and
for nerves controls (n ¼ 4), FAP 0 (n ¼ 6) and FAP patients (n ¼ 5).
*p < 0.05 and **p < 0.02, compared to control groups.
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Fig. 2 ERK1/2 increased activation in FAP. (a) Representative
pERK1/2 (upper panel) and tERK1/2 (lower panel) immunohisto-
chemistry of SG biopsies from control individuals (left panel), FAP 0
(middle panel) and FAP patients (right panel). Arrows, nuclear trans-
location. Arrow heads, cytoplasmic localization. Bar, 20 lm. Chart
(SG), Quantitation of immunohistochemical images of the ratio
between pERK1/2 and tERK1/2 staining in control individuals (n ¼ 5),
FAP 0 (n ¼ 3) and FAP patients (n ¼ 6) SG excretory ducts. Data are
represented as occupied area in squared pixels ± SD. ***p < 0.001. (b)
Representative pERK1/2 (upper panel) and tERK1/2 (lower panel)
immunohistochemistry of nerves from control individuals (left panel),
FAP 0 (middle panel) and FAP patients (right panel). Bar, 20 lm.
Chart (Nerve), Quantitation of immunohistochemical images of the
ratio between pERK1/2 and tERK1/2 staining in control individuals
(n ¼ 5), FAP 0 (n ¼ 7) and FAP patient (n ¼ 5) nerves. Data are
represented as occupied area in squared pixels ± SD. **p < 0.002,
***p < 0.001. (c) ERK1/2 activation in TTR V30M mice peripheral
nerve; Immunoblots representing stimulation of pERK1/2 (top lanes)
and expression of tERK1 (bottom lane) from peripheral nerve extracts
of TTR V30M mice. 20 lg of total protein was loaded per lane. Chart:
quantitation of immunoblot images of the ratio between phos-
pho-ERK1/2 (p-p44/42) and total-ERK1 (p44). **p < 0.007 and
***p < 0.0001, comparing older (n ¼ 6) to younger (n ¼ 6) TTR V30M
mice.
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since age-matched wild type and TTR-null mice did not
show differences on ERK1/2 activation (data not shown). It
is possible that low amounts of pre-ﬁbrillar TTR species are
present in old transgenic TTR V30M mice not detected by
immunohistochemistry. Taken together, the human and mice
data point to ERK1/2 up-regulation in FAP tissues.
MEK1/2 activation is up-regulated in FAP
One of the signaling mechanisms that up-regulates ERK1/2
activity are upstream kinases. The immediate upstream ERK1/
2 kinase isMEK1/2. Consistent with the human nerve ERK1/2
data, we found MEK1/2 activation (phospho/total levels) up-
regulated in FAP nerves both from asymptomatic carriers and
patients, relatively to controls (Fig. 3 and chart). As observed
for ERK1/2, in a later symptomatic stage, phosphorylation
levels of MEK1/2 decreased; however, tMEK1/2 levels were
also lower, leading to sustained MEK1/2 activation, when
compared to normal specimens. To note that axonal staining is
signiﬁcantly decreased for tERK1/2 and tMEK1/2 due to
severe loss of nerve ﬁbers in patients.
ERK1/2 activation is RAGE mediated
The RN22 cellular system, that presents a Schwann cell
like phenotype and was previously demonstrated to display
RAGE mediated neurotoxicity triggered by TTR aggre-
gates (Sousa et al. 2001a), was used to determine whether
TTR aggregates could activate the ERK1/2 MAPK
cascade. We found that treatment of RN22 cells with
TTR aggregates triggered a rapid and sustained ERK1/2
phosphorylation after 15 min, while soluble TTR had no
effect (Fig. 4a). Then, we posed the question whether
RAGE was mediating ERK1/2 activation stimulated by
TTR aggregates. In fact, we found that TTR aggregates-
induced ERK1/2 activation was RAGE mediated, as anti-
RAGE IgG had a signiﬁcant inhibitory effect in ERK1/2
activation, when compared with non-immune IgG at the
same concentration [Fig. 4b and charts (i) (ii)]. Previous
studies demonstrated that prolonged exposure of RN22
cells to TTR aggregates (24 h) leads to a RAGE-dependent
activation of caspase-3 (Sousa et al. 2001a). Here, we
investigated whether ERK1/2 is mediating intracellular
signaling leading to induction of apoptosis stimulated by
TTR aggregates. Using the described cell culture apoptosis
assay (Sousa et al. 2001a) we blocked the ERK1/2
signaling pathway with U0126, a MEK1/2 pharmacologi-
cal inhibitor. U0126 completely abolished TTR aggregates-
dependent caspase-3 activation, whereas control U0126
and soluble TTR did not activate caspase-3 (Fig. 4c).
Fig. 3 MEK1/2 increased activation in FAP nerves. pMEK1/2 (upper
panels) and tMEK1/2 (lower panels) immunohistochemistry of repre-
sentative nerves from control individuals (left panels), FAP 0 (middle
panels) and FAP patients (right panels). Bar, 20 lm. Chart, Quanti-
tation of immunohistochemical images of the ratio between pMEK1/2
and tMEK1/2 staining in control individuals (n ¼ 5), FAP 0 (n ¼ 7) and
FAP patients (n ¼ 6). Data are represented as occupied area in
squared pixels ± SD. **p < 0.01 and ***p < 0.001.
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Discussion
This study addresses early intracellular signaling events
occurring as a consequence of TTR deposition in FAP. We
propose that the MEK–ERK MAPK signaling pathway is
involved in FAP pathogenesis. Supporting this hypothesis,
we show that cultured Schwann-like cells treated with TTR
aggregates elicit a sustained ERK1/2 activation, which is
transduced in part by RAGE. It is possible that other still
unknown receptors intervene in the TTR aggregates-induced
signaling cascades. It is well characterized that RAGE
signaling induces oxidative stress and activates ERK
cascades, leading to downstream increased NFjB activity
(Yan et al. 1994; Lander et al. 1997). In addition, the RAGE
promoter contains 2 functional NFjB binding sites (Li and
Schmidt 1997), therefore both the increased NFjB activation
and increased RAGE expression observed in FAP (Sousa
et al. 2000; Sousa et al. 2001a) most likely contribute to the
observed ERK sustained activation observed in this cellular
system. Moreover, it was demonstrated that the cytosolic
domain of RAGE directly binds to ERK by a D-domain
docking site (Ishihara et al. 2003). In vivo, using transgenic
mice expressing a signaling transduction deﬁcient RAGE in
peripheral neurons, a diminished phosphorylation of ERK1/2
after nerve crush injury has been observed (Rong et al.
2004). As shown previously, long exposure of RN22 cells to
TTR aggregates leads to increased activation of caspase-3,
which was mediated by RAGE (Sousa et al. 2001a). When
we posed the question whether ERK cascades could play a
role in this process, we found that in fact blockade of ERK
activation, using the MEK inhibitor U0126, abolished
caspase-3 activation. These evidences point to ERK1/2 as
an important player in mediating the cytotoxic effects of TTR
aggregates.
(a) (b)
(c)
Fig. 4 ERK1/2 activation by TTR aggregates. (a) TTR aggregates
trigger ERK1/2 MAPK activation. Immunoblot representing pERK1/2
(p-p44/42) induction in RN22 cells exposed for the indicated time
periods to either 1 lM soluble TTR (sTTR) or 1 lM TTR aggregates
(aTTR). (b) TTR aggregates activate ERK1/2 MAPK cascade via
RAGE. Immunoblots representing stimulation of phospho-ERK1/2
(p-p44/42) and expression of total-ERK1/2 (p44/42) from RN22 cell
lysates. Cells were exposed 30 min to either 1 lM soluble TTR (sTTR)
or 1 lM TTR aggregates (aTTR). Where indicated, cells were pre-
incubated with polyclonal anti-RAGE (aRAGE) or non-immune IgG
(NI). Chart (i): quantitation of immunoblot images of the ratio between
phospho- and total-ERK1 (p44), and (ii) phospho- and total-ERK2
(p42). Data are represented as fold activation relatively to non-treated
cells (media), which was set as 1. Results derive from three inde-
pendent experiments. **p < 0.003, compared with non-treated cells
and #p < 0.05, compared with cells treated with aTTR in the presence
of non-immune IgG (aTTR + NI). (c) TTR aggregates induction of
caspase-3 is ERK1/2 MAPK mediated. Activation of caspase-3 in
RN22 cells exposed for 24 h to either 2 lM soluble TTR (sTTR) or 2 lM
aggregated TTR (aTTR). Where indicated cells were pre-incubated
with 1 lM U0126 for 1 h. Then these cultures were exposed for 24 h to
aTTR (2 lM) along with 5 lM U0126. ***p < 0.001, compared with non-
treated cells (media). ###p < 0.001, compared with cells treated with
TTR aggregates.
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Data with clinical samples revealed a chronic MEK-ERK
activation starting at early asymptomatic stage (FAP 0) and
persisting throughout the course of the disease. Moreover, in a
FAP animal model, we show an increased ERK1/2 activation
in total protein extracts of peripheral nerve from older mice
(more prone to have TTR deposits) as compared with younger
animals and control mice. The cellular localization of
phosphorylated ERK (pERK) differed depending on the
tissue analyzed. In FAP SG, pERK nuclear translocation was
visualized. In FAP nerves, pERK was sequestered in axons
where ERK acts in neuronal cytoplasmic substrates that might
ultimately contribute to axon degeneration. The possibility of
pERK nuclear translocation in dorsal root ganglia has to be
considered, as TTR deposition in the stroma of sensitive
ganglia most likely affects the cell body and probably leads to
the nuclear regulation of speciﬁc gene products that then
circulate in axons.
While ERK activation occurred at the asymptomatic and
symptomatic levels both in SG and nerve, expression of the
two phosphatases investigated differed. The down-regulation
of MKP-1 (as shown by immunohistochemistry in SG and
nerve, and microarray data) in symptomatic individuals
correlated with the observed ERK up-regulation in the same
tissues, but was not evident for the asymptomatic level.
Immunohistochemical analysis of MKP-3 expression (a more
speciﬁc ERK1/2 phosphatase as compared with the other
MAPKs) differed between SG and nerves; while in SG,
MKP-3 expression was down-regulated in accordance with
the observed ERK activation in FAP 0 and FAP individuals,
in nerves MKP-3 was overexpressed at the presymptomatic
level (FAP 0). These results might derive from differences
between the two tissues analyzed, including cell speciﬁc
phosphatase expression and modulation which in FAP might
have different responses at different clinical stages. It has
been proposed that growth factors, cytokines, cell stressors or
activated oncogenes induce MKPs gene transcription via
both ERK-dependent and independent pathways (Camps
et al. 2000; Colucci-D’Amato et al. 2003). In this context,
active ERK can generate a negative feedback loop leading to
the up-regulation of MKPs expression. Modulation of ERK
activity by MKPs entails not only MKP expression level but
also activity. In fact, recently, several phosphatases have been
shown to be redox-sensitive and can be either reversibly or
irreversibly inhibited, depending on the extension and
mechanism of oxidation (Meng et al. 2002; Tonks 2003).
Possible down-regulation of MKPs activity caused by
oxidative stress, which occurs in FAP tissues both at the
asymptomatic and symptomatic levels, can also modulate
ERK activity.
Although ERK signaling pathways are generally thought
to promote neuronal survival, there is a growing number of
recent studies implicating ERK activation mediating neur-
onal injury. Neuronal cell lines and primary cultures exposed
to oxidative stressors were protected by inhibition of ERK
phosphorylation (Oh-hashi et al. 1999; Satoh et al. 2000;
Stanciu et al. 2000; Kulich and Chu 2001). Moreover,
animal models of cerebral ischemia-reperfusion treated with
MEK inhibitors, developed neuroprotection (Alessandrini
et al. 1999; Namura et al. 2001). In neurodegenerative
diseases such as Alzheimer’s disease (AD), Parkinson’s
disease (PD) and Lewy body dementias, pERK appears to be
located within discrete, cytoplasmic granules (Pei et al.
2002; Zhu et al. 2002), and this pattern was also observed in
6-hydroxydopamine-treated neuronal cells (Zhu et al. 2002).
Despite the existence of discrete active ERK accumulations
in the cytoplasm, ERK may not be available to phosphorylate
possible downstream pro-survival substrates. Conversely,
substrates participating in pro-apoptotic pathways could be
accessible to active ERK. For example, death associated
protein kinase (DAPK) participates in various apoptotic
paradigms and was shown to interact with ERK. ERK
functions as the upstream activating kinase of DAPK, which
promotes the cytoplasmic retention of ERK, thereby inhib-
iting ERK signaling in the nucleus and promoting DAPK
activity (Chen et al. 2005).
The molecular signaling mechanisms in FAP neurodegen-
eration are not fully understood. In this study we pursued to
unravel these signaling mechanisms and we found that ERK
signaling cascade is abnormally activated. Finally, chronic
ERK activation might be an early and sustained signaling
ampliﬁer of TTR deposits-induced cytotoxicity leading to
NFkB activation, up-regulation of proinﬂammatory cyto-
kines (i.e. IL-1b, TNFa, MCSF), oxidative stress, and
ultimately to neurodegeneration in FAP.
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